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Abstract Myostatin, a member of the TGF-β superfamily of
secreted growth factors, is a negative regulator of skeletal
muscle growth. In the heart, it is expressed at lower levels
compared to skeletal muscle but up-regulated under disease
conditions. Cre recombinase-mediated inactivation of
myostatin in adult cardiomyocytes leads to heart failure and
increased mortality but cardiac function of surviving mice is
restored after several weeks probably due to compensatory
expression in non-cardiomyocytes. To study long-term effects
of increased myostatin expression in the heart and to analyze
the putative crosstalk between cardiomyocytes and fibro-
blasts, we overexpressed myostatin in cardiomyocytes.
Increased expression of myostatin in heart muscle cells caused
interstitial fibrosis via activation of the TAK-1-MKK3/6-p38
signaling pathway, compromising cardiac function in older
mice. Our results uncover a novel role of myostatin in the
heart and highlight the necessity for tight regulation of
myostatin to maintain normal heart function.
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Introduction
Intercellular communication between cardiomyocytes and
cardiac fibroblasts plays an important role in pathologic re-
modeling of the heart. Cross-talk between different cell pop-
ulations in the heart is regulated via release of proteins regu-
lating tissue homeostasis and response to cardiac injury
(Shimano et al. 2012). A major mediator of interactions be-
tween cardiomyocytes and fibroblasts is TGF-β1
(transforming growth factor β1). Myostatin (also called
GDF-8) belongs to the TGF-β superfamily of secreted growth
factors and was first identified as a negative regulator of skel-
etal muscle growth (McPherron et al. 1997). Inactivation of
myostatin by targeted deletion or by naturally occurring mu-
tations leads to a dramatic skeletal muscle hypertrophy in
several species including mice, cattle, sheep, dogs and human
beings (McPherron et al. 1997; Rodgers and Garikipati 2008).
In addition to its function in restricting skeletal muscle growth,
myostatin also enables profibrotic responses in skeletal mus-
cle. Genetic inactivation of myostatin or treatment with inhib-
itory peptides decreases fibrosis after musculoskeletal injury
or in dystrophic mice (Bogdanovich et al. 2002; McCroskery
et al. 2005; Nakatani et al. 2008; Wagner et al. 2002).
Furthermore, myostatin promotes proliferation, differentiation
and expression of extracellular matrix proteins of fibroblasts
in skeletal muscles (Li et al. 2008; Zhu et al. 2007).
Recently, we demonstrated that inactivation of myostatin in
adult cardiomyocytes leads to cardiac hypertrophy and heart
failure. Interestingly, cardiac dysfunction is rescued after in-
activation of myostatin in cardiomyocytes within a matter of
several weeks, probably by compensatory expression of
myostatin by non-cardiomyocytes indicating a close interac-
tion between cardiomyocytes and fibroblasts (Biesemann
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et al. 2014). Analysis of the effects of myostatin on cardiac
fibroblasts using germ-line myostatin knockout mice has not
so far yielded conclusive results, revealing reduced fibrosis in
aging mice (Morissette et al. 2009) but unchanged cardiac
fibrosis in dystrophin-deficient mdx mice (Cohn et al. 2007).
Furthermore, it has been recently postulated that in-
creased expression of GDF11, which is highly similar
to myostatin, reverses age-related cardiac hypertrophy
(Loffredo et al. 2013), implying potential benefits of
increased expression of GDF11 and myostatin that are
both signaling via the same receptors (Andersson et al.
2006; Oh et al. 2002). To better understand the
crosstalk between cardiomyocytes and fibroblasts, we
asked whether cardiomyocyte-derived myostatin has an
impact on non-cardiomyocytes in the myocardium.
Therefore, we specifically overexpressed myostatin in
cardiomyocytes in mice, which was associated with ac-
tivation of the TAK1-MKK3/6-p38 signaling pathway
and caused an increase in inters t i t ia l f ibrosis
compromising cardiac function in older mice.
Materials and methods
Generation and treatment of transgenic mouse lines
All procedures were performed in accordance with the guide-
lines for animal experimentation of the local authorities. All
animals were kept on the identical C57/BL6/J background.
For all studies, male mice were used. Transgenic mice were
generated as described before (Biesemann et al. 2014). Cre
recombination in αMyHC-MCMmice was achieved by intra-
peritoneal administration of tamoxifen for five consecutive
days.
Physiological measurements
Cardiac MRI measurements were performed on a 7.0 T
Bruker Pharmascan, equipped with a 300mT/m gradient sys-
tem, using a custom-built circularly polarized birdcage reso-
nator and the IntraGate™ self-gating tool (Bruker, Ettlingen,
Germany). Mice were analyzed under volatile isoflurane (1.5–
2.0 %) anaesthesia. Measurements were based on the gradient
echo method (repetition time=6.02 ms; echo time=1.6 ms;
field of view=2.20×2.20 cm; slice thickness=1.0 mm; ma-
trix=128×128; repetitions=100). The imaging plane was lo-
calized using scout images showing 2- and 4-chamber views
of the heart, followed by acquisition in the short axis view,
orthogonal on the septum in both scouts. Multiple contiguous
short-axis slices were acquired for coverage of the left ventri-
cle. MRI data were analysed using Qmass digital imaging
software (Medis, Leiden, Netherlands).
RT-PCR analysis
For treatment with pharmacological inhibi tors ,
cardiomyocytes were stimulated with different reagents
as indicated. RNA was isolated from either ventricular
tissue or isolated cell population according to standard
protocols using the Trizol reagent (Invitrogen,
Karlsruhe, Germany) and subjected to RT-PCR analysis
using a Bio-Rad iCYCLER iQ5 Real-time PCR machine
with Arp (acidic ribosomal protein) as internal standard,
as described before (Neuhaus et al. 2003).
Western blot analysis
Ventricular tissue was minced in liquid nitrogen and lysed by
standard procedures. Next, 10–20 μg of lysed ventricular tis-
sue or isolated cardiomyocytes were separated by SDS-PAGE
and incubated with different antibodies. Antibodies recogniz-
ing p-p38 (Thr180/Tyr182), p38, p-TAK1 (Thr187), p-
MKK3/6 (Ser189/207) and p-HSP27 (Ser82) were from Cell
Signaling. The antibody against RALA was from BD and
anti-α-tubulin from Sigma. Immunoreactive proteins were vi-
sualized on a VersaDoc (BioRad) and quantified with the
QuantityOne software (BioRad).
Morphological analysis
Midventricular parts of the heart were cut into 10-μm-thick
sections using a Leica CM 1950 cryostat (Leica). Masson’s
Trichrome staining was performed according to the ACCU
STAIN® protocol (Sigma). Images were taken with an Axio
Imager.Z1 microscope (Carl Zeiss). The extent of fibrosis was
determined by analyzing ×10 images with Masson’s
Trichrome using ImageJ software. To measure cardiomyocyte
area, sections were fixed and incubated with TRITC-labeled
Lectin from Triticum vulgaris (Sigma, Steinheim, Germany)
followed by analysis of four random areas (×20 images) per
tissue block (n=3 per mouse model) using ImageJ software.
For Collagen I staining, cryosections were probed with a
Collagen I antibody (Rockland) and secondary antibodies.
Sections without primary antibodies served as negative con-
trols. For each mouse, at least five random microscopic fields
per each tissue block (n=3 per mouse model and time point)
were analyzed with a Leica SP2 confocal scanning micro-
s cope us ing a ×40 P lanapo ob j ec t i ve (Le i ca ) .
Immunolabeled cryosections were analyzed using
BQuantification^ and BVoxelShop^ options of Imaris 5
(Bitplane) and Image J software. The area of specific labeling
for Collagen I was calculated as percent of positive labeling
per tissue area as previously described (Vakhrusheva et al.
2008).
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Statistical analysis
Data are shown as mean ± SEM. Statistical analysis was
performed using GraphPad Prism (v.5.0; GraphPad
Software). Two groups were compared using the
Student’s t test, three or more groups using one-way
ANOVA followed by Bonferroni’s multiple comparison
test. Values of P < 0.05 were considered as statistically
significant.
Results
Local increase of myostatin signaling causes interstitial
fibrosis in the heart
Previous studies indicated that myostatin promotes fibrosis in
skeletal muscle (Wagner et al. 2002) and that constitutive loss
of myostatin protects from cardiac fibrosis during aging
(Morissette et al. 2009). To analyze whether increased
Fig. 1 Overexpression of
myostatin in cardiomyocytes
induces cardiac interstitial
fibrosis. Immunofluorescence
staining for F-Actin/DAPI (a–
a^), Collagen-I/DAPI (b–b^) and
F-Actin/Collagen-I/DAPI (c–c^)
in hearts of 4.5-month-old
αMyHC-Cre (a–c), αMyHC-
Cre/Mstnfl/fl (a’–c’) and αMyHC-
Cre/CAGG-Mstn (a^–c^) mice.
Scale bar 20 μm. (d) Analysis of
collagen content in hearts from
αMyHC-Cre, αMyHC-Cre/
Mstnfl/fl and αMyHC-Cre/
CAGG-Mstn mice. Collagen
content was analyzed out of ×10
pictures from trichrome staining.
Values represent means ± SEM;
**P < 0.01
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expression of myostatin in cardiomyocytes induces cardiac
fibrosis, we generated αMyHC-Cre/CAGG-Mstn mice, in
which the myostatin cDNA is expressed under control of
the CAG promoter following removal of a flox-stop cas-
sette by cre recombinase specifically in cardiomyocytes.
Interestingly, we detected increased interstitial fibrosis in
αMyHC-Cre/CAGG-Mstn mice starting at 4.5 months
(Fig. 1a^–c^, d). In contrast, age-matched αMyHC-Cre
controls (Fig. 1a–d) and αMyHC-Cre/Mstnfl/fl mice
(Fig. 1a’–c’, d), in which the myostatin gene was constitu-
tively deleted in the cardiomyocyte lineage, did not develop
fibrosis.
Next, we wanted to know whether myostatin needs to be
delivered by cardiomyocytes to induce cardiac fibrosis or
whether increased expression of myostatin in non-
cardiomyocytes of the heart exerts similar effects. For this
purpose, we used αMyHC-MCM/Mstnfl/fl mice (Biesemann
et al. 2014), which are characterized by a massive increase of
myostatin expression in non-cardiomyocytes, 6 weeks after
induced deletion of myostatin in cardiomyocytes (Fig. 2a).
We observed an increased collagen I deposition and interstitial
fibrosis 6 weeks after tamoxifen administration (Fig. 2b, d–d^,
e–e^, f–f^). The increase in collagen I deposition paralleled
the increase of myostatin expression in non-cardiomyocytes
(Fig. 2a). No fibrosis was detected in tamoxifen-treated and
untreated αMyHC-MCM control mice (Fig. 2b, c–c^).
Long-term overexpression of myostatin slightly impairs
cardiac function
Despite the development of interstitial fibrosis, we did not
detect impaired cardiac function in myostatin overexpressing
male αMyHC-Cre/CAGG-Mstn mice at 4.5 months of age.
Therefore, we wondered whether older αMyHC-Cre/CAGG-
Mstn mice (9 months), which maintain high levels of
myostatin in the heart (Fig. 3d) and show large patches of
fibrotic areas in the myocardium together with interstitial
and perivascular fibrosis in the heart (Fig. 3b’), develop car-
diac dysfunction. Assessment of cardiac function by MRI re-
vealed significantly decreased ejection fraction and stroke vol-
ume as well as increased endsystolic and enddiastolic volumes
at 9 months of age (Fig. 3e f, h–i). Since the long-term over-
expression of myostatin did not affect the cardiomyocyte area
(Fig. 3a’, c), we concluded that the impaired cardiac function
in 9-month old αMyHC-Cre/CAGG-Mstn mice is due to in-
creased cardiac fibrosis.
Myostatin activates TAK1-MKK3/6-p38 MAPK pathway
To characterize the molecular mechanism causing cardiac fi-
brosis in αMyHC-MCM/Mstnfl/fl and αMyHC-Cre/CAGG-
Mstn mice, we screened for activation of putative pro-
fibrotic pathways focusing on p38, a well-known activator
of cardiac fibrosis (Turner 2011; Zhang et al. 2003). So far,
the effects of myostatin on p38 activation have been contro-
versial: in vitro data obtained in skeletal muscle C2C12 cells
suggested that myostatin activates p38 (Philip et al. 2005) but
opposite effects were observed in neonatal rat cardiomyocytes
(Morissette et al. 2006). In vivo, we detected a strong up-
regulation of p38 phosphorylation in αMyHC-Cre/CAGG-
Mstn as well as in αMyHC-MCM/Mstnfl/fl mice, which show
a massive compensatory increase of myostatin expression in
non-cardiomyocytes (Fig. 4a–b’). Since p38 is strongly acti-
vated by TGF-beta activated kinase 1 (TAK1) and mitogen-
activated protein kinase kinase 3/6 (MKK3/6) (Sorrentino
et al. 2008; Yamaguchi et al. 1995), we examined the phos-
phorylation status of TAK1 and MKK3/6 in hearts of
αMyHC-Cre/CAGG-Mstn andαMyHC-MCM/Mstnfl/fl mice.
We observed an increase of TAK1 and MKK3/6 phosphory-
lation in both strains (Fig. 4a–b’), which corresponds well to
our previous findings that effects of myostatin on AMPK are
mediated by TAK1 (Biesemann et al. 2014). However, in
contrast to the significant increase of MKK3/6 phosphoryla-
tion the increase in TAK1 phosphorylation was not seen in all
αMyHC-Cre/CAGG-Mstn and αMyHC-MCM/Mstnfl/fl ani-
mals impeding statistical significance.
Myostatin induces interstitial fibrosis via p38 activation
To demonstrate that myostatin induces fibrosis and activates
collagen I expression via stimulation of p38 phosphorylation,
we treated isolated primary adult ventricular cardiomyocytes
in culture for 30minwith recombinant myostatin.We detected
a strong activation of p38 phosphorylation in isolated
cardiomyocytes (Fig. 5a, a’) by myostatin, concomitant with
a clear up-regulation of collagen I expression (Fig. 5b).
Interestingly, myostatin-induced expression of collagen I
was blocked by treatment of cardiomyocytes with
SB203580 (Fig. 5b). SB203580 efficiently inhibits actions
of activated p38 as demonstrated by suppression of HSP27
phosphorylation, a direct target of p38 (Fig. 5a). Taken togeth-
er, our results indicate that continuous stimulation of the myo-
cardium by myostatin induces cardiac fibrosis most likely via
TAK1 and p38 (Fig. 5c).
Fig. 2 Compensatory increase of myostatin expression in non-
cardiomyocytes after deletion of myostatin in adult cardiomyocytes
induces cardiac interstitial fibrosis. a Quantitative RT-PCR analysis of
myostatin expression in ventricles of αMyHC-MCM and αMyHC-
MCM/Mstnfl/fl mice (three independent experiments, n=3). b Analysis
of collagen I content in the mid-ventricular area of αMyHC-MCM and
αMyHC-MCM/Mstnfl/fl mice. Mean collagen I content was measured in
five different microscopic fields per heart section (n=3). c–f”
Immunofluorescence staining for collagen I in hearts of αMyHC-MCM
mice 84 days after tamoxifen injection (c–c”) and of αMyHC-MCM/
Mstnfl/fl mice 10 (d–d”), 42 (e–e”) and 120 (f–f”) days after tamoxifen
injection. Scale bar 30 μm. Values represent means ± SEM; *P < 0.05,
**P < 0.01, ****P < 0.0001
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Discussion
We demonstrated here that increased expression of
myostatin in the heart promotes fibrosis after both directed
expression in cardiomyocytes and compensatory increase in
non-cardiomyocytes after genetic inact ivation in
cardiomyocytes. These observations correspond well to the
established profibrotic role of myostatin in skeletal muscle
(Bogdanovich et al. 2002; McCroskery et al. 2005).
However, in the heart, the situation has been less clear and a
direct proof of a profibrotic effect of myostatin was missing
(Cohn et al. 2007; Morissette et al. 2009). Interestingly, acti-
vation of myostatin in the heart is also increased during heart
failure in human patients suffering from ischemic and dilated
cardiomyopathy, which has been attributed to an anti-
hypertrophic role of myostatin counteracting increased IGF-
Fig. 3 Long-term overexpression of myostatin induces cardiac fibrosis
and favors impaired contractility. a–a’ Representative WGA staining of
CAGG-Mstn (a) and αMyHC-Cre/CAGG-Mstn (a’) mid-ventricular
heart sections at 9 months of age. Scale bar 50 μm. b–b’ Trichrome
staining of CAGG-Mstn (b) and αMyHC-Cre/CAGG-Mstn (b’) mid-
ventricular heart sections at 9 months of age. Scale bar 20 μm. c
Analysis of cardiomyocyte cross-sectional area (CSA). CSA was
determined by analysis of four different microscopic fields (×20) per
heart section (n=3). d Quantitative RT-PCR analysis of myostatin
expression in CAGG-Mstn and αMyHC-Cre/CAGG-Mstn ventricles.
Arp (acidic ribosomal protein) was used for normalization. (n=3). e, f,
h–j MRI analysis of CAGG-Mstn and αMyHC-Cre/CAGG-Mstn mice.
Male mice at 9 months of age were used (n=3). e Ejection fraction. f
Stroke volume. h Endsystolic volume (ESV). i Enddiastolic volume
(EDV). j Left ventricular (LV) mass. g Body weight of CAGG-Mstn
and αMyHC-Cre/CAGG-Mstn mice. Male mice at 9 months of age
were used (n=6 (CAGG-Mstn), n=4 (αMyHC-Cre/CAGG-Mstn)). All
measurements represent means ± SEM. *P < 0.05, **P < 0.01
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Fig. 4 Myostatin activates
TAK1-MKK3/6-p38 pathway.
a–a’Western blot analysis (a) and
quantitation (a’) of p-TAK1
(Thr187), p-MKK3/6 (Ser189/
297), p-p38 (Thr180/Tyr182) and
p38 in αMyHC-Cre and
αMyHC-Cre/CAGG-Mstn hearts
(three independent experiments,
n≥3). b–b’p-TAK1 (Thr187), p-
MKK3/6 (Ser189/297), p-p38
(Thr180/Tyr182) and p38 in
αMyHC-MCM and αMyHC-
MCM/Mstnfl/fl hearts 6 weeks
after tamoxifen administration
(three independent experiments,
n≥3). Values represent means ±
SEM; *P < 0.05, **P < 0.01,
****P < 0.0001
Fig. 5 Myostatin induces fibrosis via the p38 signaling pathway. a, a’, b
Murine adult ventricular wildtype cardiomyocytes (1 day in culture) were
stimulated with DMSO (1 h), 30 ng/ml myostatin (Mstn, 30 min), 10 μM
SB203580 (SB, 1 h) or preincubated with 10μMSB203580 (SB, 30 min)
and then stimulated with 30 ng/ml myostatin (30 min). a p-p38 (Thr180/
Tyr182) and p-Hsp27 (Ser82) in treated cardiomyocytes (three
independent experiments, n=3). a’ Quantitation of p-p38 in non-
stimulated and myostatin-stimulated cardiomyocytes (three independent
experiments, n=3). b Quantitative RT-PCR of Col1a1 expression (three
independent experiments, n=3) in treated cardiomyocytes. c Simplified
model of myostatin signaling inducing fibrosis mechanism: myostatin
stimulates p38 via activation of TAK1 and MKK3/6, which then
promotes collagen I expression. Values represent means ± SEM; *P
< 0.05, ***P < 0.001
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1 signaling (George et al. 2010). Our own findings demon-
strating a transient increase in cardiomyocyte hypertrophy af-
ter induced inactivation of myostatin in adult cardiomyocytes
support this view (Biesemann et al. 2014). However, cardiac
fibrosis is an unwanted side effect of increased myostatin sig-
naling, which is otherwise beneficial and prevents heart fail-
ure. In this context, it is important to note that increased ex-
pression of myostatin does not compromise cardiac function
in 4.5-month-old mice despite a moderate increase in fibrosis.
The situation is different in 9-month-old mice, which show
increased fibrosis with large patches of fibrotic tissue in the
myocardium and impaired cardiac function. Tight regulation
ofmyostatin up-regulation seemsmandatory to restrict cardiac
hypertrophy and prevent organ fibrosis in a pathological
situation in order to maintain cardiac function. We hypothe-
size that a limited up-regulation of myostatin in pathological
conditions in the heart might help to restrict hypertrophy and
improve cardiac contractility with only minor adverse effects,
while negative side effects such as cardiac fibrosis seem to
dominate after extended activation of myostatin (Breitbart
et al. 2011; George et al. 2010; Sharma et al. 1999). GDF11
has been claimed to reverse age-related cardiac hypertrophy
arguing for continuous administration of GDF11 to prevent
age-related organ dysfunction (Loffredo et al. 2013; Sinha
et al. 2014). Since GDF11 utilizes the same receptors as
myostatin (Andersson et al. 2006; Oh et al. 2002), it
seems likely that GDF11 will also induce fibrosis when
administered at high doses for an extended time. Careful
adjustment of GDF11 levels might prevent adverse con-
sequences and limit counter-regulatory effects, although
much needs to be learned about the intricate regulatory
network that regulates GDF11 and myostatin levels in
different organs.
Activation of p38 and its upstream kinases MKK3/6 are
well known to induce organ fibrosis (Liao et al. 2001;
Turner 2011; Zhang et al. 2003). However, activation of p38
signaling has not been linked to the profibrotic activities of
myostatin in skeletal muscle (Wagner et al. 2002). Our data
clearly indicate that increased expression of myostatin results
in enhanced phosphorylation of TAK1, MKK3/6 and p38,
which was further validated in isolated adult cardiomyocytes
by demonstrating that inhibition of p38 blocked myostatin-
depended stimulation of Collagen I expression. In contrast to
our results, Morissette et al. (2006) observed that adenoviral
expression of myostatin did not increase p38 phosphorylation
but reversed phenylephrine-induced activation of p38 in neo-
natal rat cardiomyocytes in vitro. Since we analyzed adult
murine heart samples and primary mouse cardiomyocytes in
our experiments, this discrepancy might reflect stage-
dependent differences of myostatin on p38 signaling. Further
support for this idea comes from the analysis of the adult
murine myoblast cell line C2C12, in which myostatin also
activates p38 (Philip et al. 2005).
Taken together, our study establishes a profibrotic role of
myostatin in the heart, which is exerted via the p38 signaling
pathway, compromising cardiac functions upon extended ex-
posure to myostatin. We postulate that myostatin levels in the
heart need to be tightly regulated in pathological conditions to
avoid adverse effects. Long-term therapeutic interventions by
continuous manipulation of myostatin or GDF11 levels might
initiate unwanted side effects such as fibrosis or exacerbate an
already existing organ fibrosis.
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